12,356 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by J. Goldman & Co LP

J. Goldman & Co LP bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, HoldingsChannel reports. The fund bought 12,356 shares of the company’s stock, valued at approximately $1,176,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Algert Global LLC boosted its holdings in shares of Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the last quarter. AlphaCentric Advisors LLC lifted its position in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after purchasing an additional 626 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

ORKA opened at $101.82 on Wednesday. The firm has a fifty day moving average price of $93.17 and a 200 day moving average price of $66.41. Oruka Therapeutics, Inc. has a 1 year low of $14.34 and a 1 year high of $115.51. The stock has a market cap of $6.74 billion, a P/E ratio of -50.16 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities analysts expect that Oruka Therapeutics, Inc. will post -2.27 EPS for the current year.

Insider Activity

In related news, Director Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.13, for a total value of $1,572,104.21. Following the completion of the transaction, the director owned 51,326 shares in the company, valued at $3,599,492.38. The trade was a 30.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 83,116 shares of company stock worth $6,636,533. 23.49% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ORKA shares. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Wedbush reaffirmed an “outperform” rating and set a $165.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.